白蛋白结合型紫杉醇在乳腺癌新辅助化疗中的应用

The application of albumin-bound paelitaxel in neoadjuvant chemotherapy for breast cancer

目的评价白蛋白结合型紫杉醇联合表阿霉素及环磷酰胺在乳腺癌新辅助化疗中的疗效及不良反应。方法确诊乳腺癌的18例患者采用白蛋白结合型紫杉醇＋表阿霉素＋环磷酰胺方案行新辅助化疗，完成4疗程后进行手术并评价疗效及不良反应。结果本新辅助化疗方案的病理完全缓解（pCR）率为38．9％，总有效率（cCR＋cPR）为88．9％；主要不良反应为骨髓抑制（83．3％）、胃肠道反应（61．1％）和感觉神经毒性（22．2％），所有患者均能耐受，未发生过敏反应。结论自蛋白结合型紫杉醇联合表阿霉素及环磷酰胺方案在乳腺癌新辅助化疗中的疗效显著，毒副反应少，患者耐受好。

Objective To assess the efficacy and adverse reactions of albumin-bound paelitaxel comhined with epirubicin and cyclophosphamide in neoadjuvant chemotherapy for patients with breast cancer. Methods 18 patients with breast cancer received neoadjuvant chemotherapy with albuminbound paclitaxel combined with epirubicin and cyclophosphamide for four cycles, and then underwent surgery. The efficay and adverse reactions were assessed. Results The pCR rate was 38.9% and the total effective rate （ cCR puls cPR ） was 88.9%. The major adverse reactions which all the patients could tolerate included bone marrow suppression, gastrointestinal tract reaction, and sensory neurotoxieity. No allergic response occurred. Conclusions The neoadjuvant chemotherapy with albumin-bound paclitaxel combined with epirubicin and cyclophosphamide for breast cancer is significantly effective, and has fewer adverse reactions and a good tolerance.